Literature DB >> 22700443

Cancer treatment and survivorship statistics, 2012.

Rebecca Siegel1, Carol DeSantis, Katherine Virgo, Kevin Stein, Angela Mariotto, Tenbroeck Smith, Dexter Cooper, Ted Gansler, Catherine Lerro, Stacey Fedewa, Chunchieh Lin, Corinne Leach, Rachel Spillers Cannady, Hyunsoon Cho, Steve Scoppa, Mark Hachey, Rebecca Kirch, Ahmedin Jemal, Elizabeth Ward.   

Abstract

Although there has been considerable progress in reducing cancer incidence in the United States, the number of cancer survivors continues to increase due to the aging and growth of the population and improvements in survival rates. As a result, it is increasingly important to understand the unique medical and psychosocial needs of survivors and be aware of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship. To highlight the challenges and opportunities to serve these survivors, the American Cancer Society and the National Cancer Institute estimated the prevalence of cancer survivors on January 1, 2012 and January 1, 2022, by cancer site. Data from Surveillance, Epidemiology, and End Results (SEER) registries were used to describe median age and stage at diagnosis and survival; data from the National Cancer Data Base and the SEER-Medicare Database were used to describe patterns of cancer treatment. An estimated 13.7 million Americans with a history of cancer were alive on January 1, 2012, and by January 1, 2022, that number will increase to nearly 18 million. The 3 most prevalent cancers among males are prostate (43%), colorectal (9%), and melanoma of the skin (7%), and those among females are breast (41%), uterine corpus (8%), and colorectal (8%). This article summarizes common cancer treatments, survival rates, and posttreatment concerns and introduces the new National Cancer Survivorship Resource Center, which has engaged more than 100 volunteer survivorship experts nationwide to develop tools for cancer survivors, caregivers, health care professionals, advocates, and policy makers. Published 2012 American Cancer Society, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22700443     DOI: 10.3322/caac.21149

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  1118 in total

1.  Wireless, battery-free, flexible, miniaturized dosimeters monitor exposure to solar radiation and to light for phototherapy.

Authors:  Seung Yun Heo; Jeonghyun Kim; Philipp Gutruf; Anthony Banks; Pinghung Wei; Rafal Pielak; Guive Balooch; Yunzhou Shi; Hitoshi Araki; Derrick Rollo; Carey Gaede; Manish Patel; Jean Won Kwak; Amnahir E Peña-Alcántara; Kyu-Tae Lee; Yeojeong Yun; June K Robinson; Shuai Xu; John A Rogers
Journal:  Sci Transl Med       Date:  2018-12-05       Impact factor: 17.956

2.  Does training and experience influence the accuracy of computed tomography colonography interpretation?

Authors:  Greg Rosenfeld; Yi Tzu Nancy Fu; Brendan Quiney; Hong Qian; Darin Krygier; Jacquie Brown; Patrick Vos; Pari Tiwari; Jennifer Telford; Brian Bressler; Robert Enns
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

3.  Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.

Authors:  Michaela A Dinan; Yanhong Li; Yinghong Zhang; Suzanne B Stewart; Lesley H Curtis; Daniel J George; Shelby D Reed
Journal:  Clin Genitourin Cancer       Date:  2015-08-06       Impact factor: 2.872

4.  Acute Menopausal Symptoms in Young Cancer Survivors Immediately following Chemotherapy.

Authors:  Katherine E Cameron; Martha B Kole; Mary D Sammel; Jill P Ginsberg; Yasmin Gosiengfiao; Jennifer E Mersereau; H Irene Su; Clarisa R Gracia
Journal:  Oncology       Date:  2018-01-26       Impact factor: 2.935

5.  ZWINT is the next potential target for lung cancer therapy.

Authors:  Fang Peng; Qiang Li; Shao-Qing Niu; Guo-Ping Shen; Ying Luo; Ming Chen; Yong Bao
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-14       Impact factor: 4.553

Review 6.  Review of Colorectal Studies Using the National Cancer Database.

Authors:  Katherine A Kelley; V Liana Tsikitis
Journal:  Clin Colon Rectal Surg       Date:  2019-01-08

Review 7.  Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.

Authors:  Jean Domercant; Nichole Polin; Eiman Jahangir
Journal:  Ochsner J       Date:  2016

Review 8.  Emerging Systemic Therapies for Colorectal Cancer.

Authors:  Christine M Veenstra; John C Krauss
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

9.  Growth inhibitory effects of large subunit ribosomal proteins in melanoma.

Authors:  Gregory R Kardos; Mu-Shui Dai; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2014-06-16       Impact factor: 4.693

10.  A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis.

Authors:  Kantima Leelahavanichkul; Panomwat Amornphimoltham; Alfredo A Molinolo; John R Basile; Sittichai Koontongkaew; J Silvio Gutkind
Journal:  Mol Oncol       Date:  2013-10-12       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.